ThomasMHabermannMD

PubMed

• 60 citations
  Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia
  Jonas Paludo, Jithma P. Abeykoon, Amanda Shreders, Stephen M. Ansell, Shaji Kumar
  Annals of Hematology. 2018-04-03
• 759 citations
  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
  Jens G. Lohr, Petar Stojanov, Michael S. Lawrence, Daniel Auclair, Bjoern Chapuy
  Proceedings of the National Academy of Sciences of the United States of America. 2012-03-06
• 43 citations
  A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group...
  Simona Sammassimo, Giancarlo Pruneri, Giovanna Andreola, Juan Montoro, Sara Steffanoni
  Hematological Oncology. 2016-12-01

Journal Articles

• Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia  
  Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
• Publisher Correction: Molecular Subtypes of Diffuse Large B Cell Lymphoma Are Associated with Distinct Pathogenic Mechanisms and Outcomes  
  Thomas M Habermann, Scott J Rodig, Rameen Beroukhim, Jeremiah A Wala, Andrew L Feldman, Todd R Golub, Margaret A Shipp, Nature
• Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome for Patients with Diffuse Large B-cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials  
  Thomas Habermann, MD, Annals of Oncology

Abstracts/Posters

• Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An Internation...
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma
  Thomas M. Habermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease? 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all